Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ganaxolone for TSC-associated seizures (Phase 3, China)
CTR20231247Phase 3Completed
- Sponsor
- Marinus Pharmaceuticals
- Start
- Apr 2023
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ganaxolone in tuberous sclerosis complex (TSC), sponsored by Marinus Pharmaceuticals. Started Apr 2023; status: completed.
02
Drugs
ganaxolone
03
Conditions
tuberous sclerosis complex (TSC)
Beyond the preview
Go deeper on CTR20231247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231247.